Dupilumab for the Treatment of Alopecia Areata in Children with Atopic Dermatitis

This case series examined the use of dupilumab, an interleukin 4 receptor antagonist, in treating alopecia areata (AA) in 6 pediatric patients (4 girls and 2 boys) aged 7 to 12 years who also had atopic dermatitis (AD). Five of the 6 patients showed improvement in AA, with 4 experiencing complete hair regrowth. One patient did not respond to the treatment. Dupilumab was generally well tolerated, with only one patient discontinuing due to severe anxiety related to injections. The study suggests that dupilumab may be a viable treatment option for AA in children with AD, though further research is needed to understand its mechanism and efficacy fully.